

Casirivimab & Imdevimab (Regeneron's antibody combination) Order Form for Post-Exposure Prophylaxis

Patient Name _____ DOB _____

Address _____

Phone # _____ ICD-10 Diagnosis: U07.1 – COVID-19

***** Casirivimab & Imdevimab (Regeneron's antibody combination) is NOT indicated for hospitalized patients, patients receiving supplemental oxygen, patients on home oxygen who are requiring increased amounts of oxygen, or for pre-exposure prophylaxis. REGEN-COV is NOT a substitute for vaccination against COVID-19*****

Post-Exposure Prophylaxis Criteria for use:

Individuals who are at high risk for progression to severe COVID-19, including hospitalization or death and were:

1. In close contact with an infected individual with SARS-CoV-2 **within the last 96 hours** (must meet 1 of the following criteria):

- Within 6 feet for a total of 15 minutes or more
- Providing care at home or living in same household as the infected individual
- Direct physical contact (hugging, kissing, etc.)
- Sharing eating or drinking utensils
- Exposure to respiratory droplets from a person (sneezing or coughing within 6 feet)
- Occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (i.e.

nursing homes, prisons)

AND

2. Are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (must meet **One (1)** of the following risk factors):

- Not fully vaccinated
- Age ≥ 65
- BMI ≥ 30
- Pregnancy
- Immunosuppressed
 - Solid organ transplant, advanced HIV, active chemotherapy, ESLD
 - Use of biologic agents for treatment of underlying disease: TNF alpha inhibitor for RA or Crohn's, chronic high dose steroids

Fully vaccinated - 2 weeks after final dose of vaccination (second dose of Moderna or Pfizer and first dose of Janssen)

- Chronic Kidney Disease
- Diabetes Mellitus
- Chronic Lung Disease: COPD, Asthma, Interstitial Lung Disease, Cystic Fibrosis, or Pulmonary Fibrosis
- Cardiovascular Disease: Hypertension, Coronary Artery Disease or Congestive Heart Failure
- Neurodevelopmental disorders (Ex. Cerebral palsy)
- Medical-related technological dependence (Ex. Tracheostomy, gastrostomy, etc.)
- Sickle Cell disease

Patients who meet the above criteria will be eligible to receive Casirivimab & Imdevimab (Regeneron's antibody combination) treatment for post-exposure prophylaxis

Casirivimab & Imdevimab (Regeneron's antibody combination) Order Form for Post-Exposure Prophylaxis

Rx:

IV Casirivimab 600mg & Imdevimab 600mg (Regeneron's antibody combination) added to 100 mL of 0.9% sodium chloride for total volume of 110 mL x 1 dose

- Infuse over 21 minutes
- Administer using a 0.2-micron filter
- Observe patient for at least 1 hour following administration
- Start primary line with 500mL 0.9% sodium chloride and give the remainder of the bag as a bolus after the Regen-Cov infusion is completed

KHN infusion reaction protocol will be utilized if a patient has an infusion-related or hypersensitivity reaction.

Pre-meds (optional):

- Tylenol 650 mg po or Tylenol 1000 mg po
 Benadryl 25 mg po or Benadryl 25 mg IV
 Methylprednisolone 40 mg IV
 Other: _____

Consider premeds for patients with allergic tendencies or who have had allergic reactions to an immunoglobulin product.

Prescriber _____ Date _____

Prescriber Signature _____

Address: _____ Phone _____ Fax: _____